HEMORR₂HAGES Score for Major Bleeding Risk
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- Intermediate Risk2–3
- High Risk4–12
The HEMORR₂HAGES Score for Major Bleeding Risk calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include hepatic renal disease. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Quantifies hemorrhage risk in elderly patients with atrial fibrillation on anticoagulation therapy. The score helps clinicians assess bleeding risk when considering anticoagulation for stroke prevention in AF patients.
Clinical Indication
The HEMORR₂HAGES Score for Major Bleeding Risk is indicated for bedside clinical practice to support Quantifies hemorrhage risk in elderly patients with atrial fibrillation on anticoagulation therapy. The score helps clinicians assess bleeding risk when considering anticoagulation for stroke prevention in AF patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
HEMORR₂HAGES Score = H (1) + E (1) + M (1) + O (1) + R (1) + R (2) + H (1) + A (1) + G (1) + E (1) + S (1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| hepatic_renal_disease | string | Yes | Hepatic or renal disease |
| ethanol_abuse | string | Yes | Ethanol (alcohol) abuse |
| malignancy | string | Yes | Malignancy history |
| older_age | string | Yes | Older age (>75 years) |
| reduced_platelet | string | Yes | Reduced platelet count or function (includes aspirin use, thrombocytopenia, blood dyscrasia) |
| rebleeding | string | Yes | Rebleeding risk (prior major bleed) |
| hypertension | string | Yes | Hypertension (uncontrolled) |
| anemia | string | Yes | Anemia (Hgb <13 g/dL for men, <12 g/dL for women) |
| genetic_factors | string | Yes | Genetic factors (CYP 2C9 single-nucleotide polymorphisms) |
| excessive_fall_risk | string | Yes | Excessive fall risk |
| stroke | string | Yes | Stroke history |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | Score 0-1 |
| 2–3 | Intermediate Risk | Score 2-3 |
| 4–12 | High Risk | Score ≥4 |
Evidence-Based References (EBM)
- Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006 Mar;151(3):713-9.
- Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012 Aug 28;60(9):861-7.